Browsing Tag
Fate Therapeutics
3 posts
Why AACR 2026 data on FT839 matters for hematologic cancer and autoimmune markets
Find out how Fate Therapeutics, Inc.’s FT839 could reshape CAR T economics and expand into autoimmune disease markets. Read the full analysis.
Fate Therapeutics reports encouraging Phase 1 progress for FT819 as off-the-shelf CAR T therapy targets durable lupus remission
Find out how Fate Therapeutics is advancing FT819 as an off-the-shelf CAR T therapy for lupus and why its Phase 1 data could reshape autoimmune treatment.
Fate Therapeutics unveils ACR 2025 results: FT819 off-the-shelf CAR T drives immune remodeling in lupus
Discover how Fate Therapeutics’ FT819 off-the-shelf CAR T therapy is reshaping lupus treatment through durable immune remodeling and long-term remission.